Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22108005 | 0.86 | ALDH1A1 (0.46) | ALDH1A1ATMMIFKMT2AMAPT | |
| SCHEMBL27571682 | 0.85 | TSHR (0.51) | ALDH1A1MIFKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27811154 | 0.83 | SMN1; SMN2 (0.44) | ALDH1A1KMT2AMAPTMEN1RAB9A | |
| SCHEMBL28861927 | 0.83 | NPC1 (0.51) | ALDH1A1KMT2AMAPTMEN1MMP1 | |
| SCHEMBL27700360 | 0.83 | ALDH1A1 (0.43) | ALDH1A1ATMMIFHTTKMT2A | |
| SCHEMBL16590551 | 0.83 | MAPT (0.44) | ALDH1A1ATMKMT2AMAPTMEN1 | |
| SCHEMBL28861926 | 0.82 | MAPT (0.56) | ALDH1A1KMT2AGAAMAPTMEN1 | |
| SCHEMBL4019989 | 0.82 | TPSAB1 (0.54) | ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2173527 | 0.82 | MEN1 (0.43) | ALDH1A1KMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL27805750 | 0.82 | MEN1 (0.43) | ALDH1A1KMT2AMAPTMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| CN-114957219-B | Degradation agent for targeted degradation of Gli1 protein, preparation method and application thereof | 苏州大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| CN-110278711-A | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | 百时美施贵宝公司 | 2019-09-24 | — | — | CN | disclosed |
| CN-109824465-A | A kind of method of bipyridyliums Mn catalyst catalysis oxidation amine synthesizing amide | 陕西师范大学 | 2019-05-31 | — | — | CN | disclosed |
| CN-108892661-A | Therapeutic compounds and composition | 艾克赛特赫拉制药有限责任公司 | 2018-11-27 | — | — | CN | disclosed |
| CN-106029064-B | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2018-08-14 | — | — | CN | disclosed |
| CN-108290872-A | Cyanopyrolidine derivatives as DUBs inhibitor | 特殊治疗有限公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-105408335-B | Pyrazolo pyrrolidin derivatives and its purposes in disease is treated | 诺华股份有限公司 | 2017-11-17 | — | — | CN | disclosed |
| CN-107001339-A | Novel compounds | 特殊治疗有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-106029064-A | Therapeutic compounds and compositions | 艾克赛特赫拉制药有限责任公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-105408335-A | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG | 2016-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | ALDH1A1 1901/4885ATM 3902/4885MIF 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.